0 Replies
... Treatment of respiratory syncytial virus (rsv) infection 158dec 05, 2006: alnylam advances a systemically delivered rnai therapeutic targeting pcsk9 for the treatment of hypercholesterolemia as new ... Contine Reading & Discuss→
0 Replies
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 29, 2012--
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), a
leading RNAi therapeutics company, today announced that management will
present a company overview at the Cowen and Company 32nd
Annual Health Care Conference on Wednesday, March 7, 2012 at 9:20 a.m.
ET at the Boston Marriott Copley Place.
A... Contine Reading & Discuss→
0 Replies
Company Also Presents Data on Liposomal Facilitation of Cell-to-Cell Transfer of Nucleic Acids
BOTHELL, WA, Feb 29, 2012 (MARKETWIRE via COMTEX) --Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based
drug discovery and development company, today reported data
demonstrating the continued advancement of the Company's clinical
program for CEQ508, the... Contine Reading & Discuss→
0 Replies
PASADENA, Calif. - February 29, 2012 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. US 8,114,983 B2 entitled, "Compositions and use of EPAS1 inhibitors." Contine Reading & Discuss→
0 Replies
LAKE OSWEGO, Ore., Feb. 29, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced the appointment of David A. Scheinberg, M.D., Ph.D. to the Company's Scientific Advisory Board (SAB).
"We are... Contine Reading & Discuss→
0 Replies
Scientists have developed a completely new way of delivering extremely high concentrations of gene-silencing siRNAs to target cells, based on nanoscale microspheres composed entirely of tightly packed, double-stranded RNA. The RNAi-microsponges developed by a multidisciplinary team at the Massachusetts Institute of Technology (MIT) are constructs of long RNA polymers comprising... Contine Reading & Discuss→
0 Replies
LAKE OSWEGO, Ore., Feb. 28, 2012 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, today announced that Mark Schwartz, Ph.D., will provide a presentation entitled, "New Horizons in Active Cancer Immunotherapy: Developing Cancer... Contine Reading & Discuss→
